Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 4/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11908598 | 1.00 | TYK2 (0.42) | TYK2LRRK2PTGESCNR2PDE4B | |
| SCHEMBL670861 | 0.92 | CNR1 (0.38) | TYK2LRRK2PTGESCNR2 | |
| SCHEMBL11907809 | 0.92 | CNR1 (0.38) | TYK2LRRK2PTGESCNR2 | |
| SCHEMBL11980752 | 0.91 | CNR2 (0.39) | TYK2LRRK2PTGESCNR2 | |
| SCHEMBL11908921 | 0.89 | TYK2 (0.41) | TYK2CNR2PDE4B | |
| SCHEMBL11908919 | 0.89 | TYK2 (0.41) | TYK2CNR2PDE4B | |
| SCHEMBL671327 | 0.88 | PTGES (0.44) | LRRK2PTGESCNR2 | |
| SCHEMBL672703 | 0.88 | PTGES (0.44) | LRRK2PTGESCNR2 | |
| SCHEMBL11908744 | 0.85 | TYK2 (0.41) | TYK2LRRK2CNR2PDE4B | |
| SCHEMBL11908746 | 0.85 | TYK2 (0.41) | TYK2LRRK2CNR2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586604-B2 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| EP-2606046-A1 | 2-(ARYLAMINO)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBOXAMIDE DERIVATIVES AND THEIR USE AS MPGES-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120208839-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| WO-2012022792-A1 | 2-(ARYLAMINO)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBOXAMIDE DERIVATIVES AND THEIR USE AS MPGES-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208839-A1 | NEW COMPOUNDS | PTGER1, PTGS1, PTGES | TYK2 4718/4885LRRK2 3541/4885PTGES 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.